Published in Eur J Pharmacol on January 22, 2011
Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev (2014) 1.37
Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology (2012) 0.92
Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice. Neuropharmacology (2013) 0.91
Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res (2012) 0.88
Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology (2013) 0.80
Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine Tob Res (2013) 0.78
The "stop" and "go" of nicotine dependence: role of GABA and glutamate. Cold Spring Harb Perspect Med (2013) 0.77
Comparison of effects produced by nicotine and the α4β2-selective agonist 5-I-A-85380 on intracranial self-stimulation in rats. Exp Clin Psychopharmacol (2016) 0.77
New mechanisms and perspectives in nicotine withdrawal. Neuropharmacology (2014) 0.77
The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats. Neuropharmacology (2015) 0.75
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A (1988) 11.96
Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature (1998) 5.59
GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature (1998) 5.03
GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature (1998) 4.33
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron (2002) 3.78
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature (1997) 3.22
Dramatic decreases in brain reward function during nicotine withdrawal. Nature (1998) 3.21
Role of heteromer formation in GABAB receptor function. Science (1999) 2.98
Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron (2006) 2.53
Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol (2001) 2.32
International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol Rev (2002) 2.15
Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav (1992) 1.96
Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc (1979) 1.93
Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits. Nature (2010) 1.86
Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci (2005) 1.84
Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology (2004) 1.72
Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav (2001) 1.67
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J Biol Chem (2004) 1.45
Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine Tob Res (2007) 1.43
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem (1995) 1.40
N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther (2003) 1.36
Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther (2006) 1.30
The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) (2003) 1.28
Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci (2007) 1.25
GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets (2007) 1.24
GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci (2003) 1.23
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther (2003) 1.20
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology (2001) 1.20
Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol (2002) 1.16
Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) (2000) 1.16
Spatial distribution of GABA(B)R1 receptor mRNA and binding sites in the rat brain. J Comp Neurol (1999) 1.14
Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs (2008) 1.12
GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus. Neuropharmacology (2005) 1.11
Involvement of GABAB receptor systems in experimental depression: baclofen but not bicuculline exacerbates helplessness in rats. Brain Res (1996) 1.11
Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats. Psychopharmacology (Berl) (2003) 1.11
SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol (2004) 1.10
Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J Biol Chem (1999) 1.10
Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther (2008) 1.08
GABAB receptors in reward processes. Adv Pharmacol (2010) 1.06
Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev (2005) 1.06
Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport (2005) 1.05
Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. Pharmacol Biochem Behav (2008) 1.04
GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. J Pharmacol Exp Ther (2004) 1.02
GABAB receptor constituents revealed by tandem affinity purification from transgenic mice. J Biol Chem (2010) 1.01
GABAB receptors make it to the top--as dimers. Trends Pharmacol Sci (1999) 1.01
Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats. Behav Pharmacol (2010) 0.99
Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety. Psychopharmacology (Berl) (2006) 0.99
GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors. Drugs Today (Barc) (2005) 0.99
Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors. Bioorg Med Chem Lett (2007) 0.98
Specific roles of GABA(B(1)) receptor isoforms in cognition. Behav Brain Res (2007) 0.98
CGP 36742: the first orally active GABAB blocker improves the cognitive performance of mice, rats, and rhesus monkeys. Behav Neural Biol (1993) 0.96
The GABA(B) agonist CGP 44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure. Neuropharmacology (1999) 0.96
Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry (2005) 0.95
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today (2003) 0.94
Effects of ethanol and GABAB drugs on working memory in C57BL/6J and DBA/2J mice. Psychopharmacology (Berl) (2004) 0.94
Effects of GABAB receptor ligands in animal tests of depression and anxiety. Pharmacol Rep (2008) 0.93
Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol (2006) 0.90
Differential sensitivity to the motor and hypothermic effects of the GABA B receptor agonist baclofen in various mouse strains. Psychopharmacology (Berl) (2005) 0.90
Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. Neuropeptides (2008) 0.90
GABAB receptors and depression. Current status. Adv Pharmacol (2010) 0.88
Point mutations in the transmembrane region of GABAB2 facilitate activation by the positive modulator N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) in the absence of the GABAB1 subunit. Mol Pharmacol (2006) 0.87
The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur Neuropsychopharmacol (2010) 0.86
The GABA(B) receptor antagonist CGP36742 attenuates the baclofen- and scopolamine-induced deficit in Morris water maze task in rats. Brain Res (1997) 0.86
Unsaturated phosphinic analogues of gamma-aminobutyric acid as GABA(C) receptor antagonists. Eur J Pharmacol (1997) 0.85
The modulatory effects of high affinity GABA(B) receptor antagonists in an active avoidance learning paradigm in rats. Psychopharmacology (Berl) (1998) 0.85
Both GABA(B) receptor agonist and antagonists decreased brain stimulation reward in the rat. Neuropharmacology (2001) 0.85
The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol (1999) 0.82
Neuroadaptive changes in the rat brain GABA(B) receptors after withdrawal from cocaine self-administration. Eur J Pharmacol (2008) 0.81
Strain-dependent effects of post-training GABA receptor agonists and antagonists on memory storage in mice. Psychopharmacology (Berl) (1993) 0.81
GABAB receptors within the ventral tegmental area are involved in the expression and acquisition of morphine-induced place preference in morphine-sensitized rats. Pharmacol Biochem Behav (2008) 0.81
The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation. Behav Brain Res (2009) 0.81
The effects of electroconvulsive therapy on GABAergic function in major depressive patients. J ECT (2008) 0.80
Antidepressant efficacy screening of novel targets in the chick anxiety-depression model. Behav Pharmacol (2009) 0.79
The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology (Berl) (2008) 0.79
Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res (1996) 0.77
Involvement of GABAB receptor systems in action of antidepressants. II: Baclofen attenuates the effect of desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Brain Res (1996) 0.76
Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc (2003) 5.34
Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci (2002) 4.02
Analysis and optimization of copper-catalyzed azide-alkyne cycloaddition for bioconjugation. Angew Chem Int Ed Engl (2009) 3.81
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev (2004) 3.53
Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed Engl (2002) 3.06
Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A (2005) 3.05
Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev (2004) 2.97
Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci (2002) 2.83
Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci (2006) 2.74
Mechanism of the ligand-free CuI-catalyzed azide-alkyne cycloaddition reaction. Angew Chem Int Ed Engl (2005) 2.62
Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron (2006) 2.53
The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci (2011) 2.36
"On water": unique reactivity of organic compounds in aqueous suspension. Angew Chem Int Ed Engl (2005) 2.21
The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry (2008) 2.08
Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology (2006) 2.05
Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci (2003) 2.03
Primary aldosteronism in hypertensive patients: clinical implications and target therapy. Eur J Clin Invest (2014) 1.99
The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci (2004) 1.90
Discovery and characterization of catalysts for azide-alkyne cycloaddition by fluorescence quenching. J Am Chem Soc (2004) 1.89
Labeling live cells by copper-catalyzed alkyne--azide click chemistry. Bioconjug Chem (2010) 1.86
Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci (2007) 1.85
Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem (2005) 1.84
Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci (2005) 1.84
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) (2003) 1.83
Generalization of amygdala LTP and conditioned fear in the absence of presynaptic inhibition. Nat Neurosci (2006) 1.78
Increased motivation for self-administered cocaine after escalated cocaine intake. Neuroreport (2003) 1.73
Ligand-accelerated Cu-catalyzed azide-alkyne cycloaddition: a mechanistic report. J Am Chem Soc (2007) 1.72
Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology (2004) 1.72
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A (2005) 1.72
Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol (2007) 1.70
Label-free quantification of membrane-ligand interactions using backscattering interferometry. Nat Biotechnol (2011) 1.67
Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice. J Neurosci (2004) 1.66
Chemical and spectroscopic evidence for an FeV-oxo complex. Science (2006) 1.64
Natural supramolecular building blocks. Wild-type cowpea mosaic virus. Chem Biol (2002) 1.64
Viral MRI contrast agents: coordination of Gd by native virions and attachment of Gd complexes by azide-alkyne cycloaddition. Chem Commun (Camb) (2007) 1.63
Inhibitors of HIV-1 protease by using in situ click chemistry. Angew Chem Int Ed Engl (2006) 1.63
Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem (2011) 1.60
Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol (2006) 1.59
NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology (2008) 1.57
Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract (2011) 1.57
Tailored ligand acceleration of the Cu-catalyzed azide-alkyne cycloaddition reaction: practical and mechanistic implications. J Am Chem Soc (2010) 1.56
Designing facial amphiphiles for the stabilization of integral membrane proteins. Angew Chem Int Ed Engl (2007) 1.55
Crosslinking of and coupling to viral capsid proteins by tyrosine oxidation. Chem Biol (2004) 1.55
Unnatural amino acid incorporation into virus-like particles. Bioconjug Chem (2008) 1.54
Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology (2005) 1.53
Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release (2007) 1.53
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology (Berl) (2004) 1.51
Benzimidazole and related ligands for Cu-catalyzed azide-alkyne cycloaddition. J Am Chem Soc (2007) 1.50
Icosahedral virus particles as addressable nanoscale building blocks. Angew Chem Int Ed Engl (2002) 1.49
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry (2010) 1.48
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) (2001) 1.47
Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) (2004) 1.47
Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology (Berl) (2006) 1.45
Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther (2004) 1.45
Nicotine withdrawal in adolescent and adult rats. Ann N Y Acad Sci (2004) 1.44
Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules (2003) 1.42
Plasma clearance of bacteriophage Qbeta particles as a function of surface charge. J Am Chem Soc (2008) 1.41
The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci (2006) 1.40
Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. Clin Biochem (2006) 1.39
In situ click chemistry: probing the binding landscapes of biological molecules. Chem Soc Rev (2010) 1.38
Thiol-selective fluorogenic probes for labeling and release. J Am Chem Soc (2009) 1.36
N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther (2003) 1.36
Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J Virol (2008) 1.34
Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci (2003) 1.34
Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology (2005) 1.34
Direct human cartilage repair using three-dimensional bioprinting technology. Tissue Eng Part A (2012) 1.33
Multivalent, bifunctional dendrimers prepared by click chemistry. Chem Commun (Camb) (2005) 1.32
Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci (2005) 1.31
Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther (2006) 1.30
Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization. J Am Chem Soc (2011) 1.30
Natural supramolecular building blocks. Cysteine-added mutants of cowpea mosaic virus. Chem Biol (2002) 1.29
Laparoscopic surgery for adrenal tumors. A retrospective analysis. Hormones (Athens) (2006) 1.29
Chemical modification of viruses and virus-like particles. Curr Top Microbiol Immunol (2009) 1.28
The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) (2003) 1.28
Core-clickable PEG-branch-azide bivalent-bottle-brush polymers by ROMP: grafting-through and clicking-to. J Am Chem Soc (2010) 1.26
On-virus construction of polyvalent glycan ligands for cell-surface receptors. J Am Chem Soc (2008) 1.26
Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci (2007) 1.25
Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs (2008) 1.24
Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles. Chembiochem (2010) 1.24
Click chemistry: function follows form. Chem Soc Rev (2010) 1.23
The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology (2010) 1.23
Head-to-tail peptide cyclodimerization by copper-catalyzed azide-alkyne cycloaddition. Angew Chem Int Ed Engl (2005) 1.23
Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol (2010) 1.21
Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol (2010) 1.21
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther (2003) 1.20
Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res (2002) 1.19
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) (2007) 1.18
Microscale NMR screening of new detergents for membrane protein structural biology. J Am Chem Soc (2008) 1.18
Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology (2005) 1.18